Insulin-resistant states, such as obesity, metabolic syndrome, and type 2 diabetes, have become a global epidemic in both children and adults. They represent major risk factors for atherosclerotic cardiovascular disease, largely due to lipid and lipoprotein abnormalities. The key mechanism underlying this metabolic dyslipidemia is hepatic and intestinal overproduction of atherogenic lipoproteins. The focus of our basic research program is to understand the cellular, molecular, and physiological regulation of intestinal chylomicron and hepatic lipoprotein production in normal and insulin resistant states.
The Adeli Lab was first to demonstrate hepatic and intestinal lipoprotein overproduction and the novel role of gut hormones (GLP-1 and GLP-2) in an insulin resistant hamster model. These observations have now been confirmed in humans. Most recently, we have discovered and reported a complex gut-brain-liver axis (via vagal and CNS receptors) that is triggered upon fat ingestion to modulate lipid and lipoprotein metabolism in healthy and diabetic states.
Our current fundamental research activities: